Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Accumulated Expenses for 4 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 146.39% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 146.39% increase, with the full-year FY2025 number at $7.5 million, up 146.39% from a year prior.
  • Other Accumulated Expenses was $7.5 million for Q4 2025 at Phathom Pharmaceuticals, up from $4.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $7.5 million in Q4 2025 to a low of $20000.0 in Q3 2023.
  • A 4-year average of $2.0 million and a median of $524000.0 in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 35.48% in 2023, then soared 2501.71% in 2024.
  • Phathom Pharmaceuticals' Other Accumulated Expenses stood at $151000.0 in 2022, then decreased by 22.52% to $117000.0 in 2023, then skyrocketed by 2501.71% to $3.0 million in 2024, then soared by 146.39% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Other Accumulated Expenses are $7.5 million (Q4 2025), $4.8 million (Q3 2025), and $4.9 million (Q2 2025).